Inventor · disambiguated record
Jiaxi Wu
Also filed as: WU JIAXI
11 granted patents·17 pending applications·16 citations·filing 2013–2025
87Inventor score
Top patents by PatentIndex Score
28 records- 0195US11725034B2IL2 agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Aug 15, 2023·4 cites·30 claims
- 0291US10633411B2Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathwayUNIV TEXAS·Filed 2019·Granted Apr 28, 2020·3 cites·30 claims
- 0388US2024400632A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0487US12091440B2IL2 and peptide-MHC complex fusion proteins and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Sep 17, 2024·1 cites·33 claims
- 0587US2025034224A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0686US11492368B2Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathwayUNIV TEXAS·Filed 2020·Granted Nov 8, 2022·1 cites·15 claims
- 0786US10508129B2Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathwayUNIV TEXAS·Filed 2019·Granted Dec 17, 2019·3 cites·15 claims
- 0885US12215131B2IgG Fc-IL2-Rα-IL2 fusions and methods of use thereofREGENERON PHARMA·Filed 2023·Granted Feb 4, 2025·0 cites·25 claims
- 0984US10336786B2Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathwayUNIV TEXAS·Filed 2013·Granted Jul 2, 2019·4 cites·17 claims
- 1083US2023312665A1Novel il2 agonists and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1182US12168681B2Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereofREGENERON PHARMA·Filed 2023·Granted Dec 17, 2024·0 cites·5 claims
- 1281US12319724B2IL2 agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Jun 3, 2025·0 cites·13 claims
- 1378US2025296969A1Il-2 variants with reduced binding to il-2 receptor alpha and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1477US10696710B2Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathwayUNIV TEXAS·Filed 2019·Granted Jun 30, 2020·0 cites·16 claims
- 1570US11834485B2IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereofREGENERON PHARMA·Filed 2021·Granted Dec 5, 2023·0 cites·25 claims
- 1670US2024067691A1Interferon receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1770US2024101633A1Interferon receptor agonists and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1868US2025114469A1METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINEREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1967US2025114468A1Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokineREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2066US2025179137A1Il18 receptor agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2166US2024270836A1Il12 receptor agonists and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2265US2024376229A1Interferon receptor antagonists and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2365US2023382969A1Interleukin-2 proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2463US2023391844A1Interleukin-2 proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2562US2024148867A1Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokineREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2660US2017296655A1Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathwayUNIV TEXAS·Filed 2017·Application pending·0 cites
- 2757US2023110958A1Il27 receptor agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2856US2025361309A1Tumor-targeted split il12 receptor agonistsREGENERON PHARMA·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jiaxi Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →